Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Media
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • ACT Tulsa
  • Contact

Progentec Gains Additional Funding for Lupus Detection and Management Platforms

    Home News Progentec Gains Additional Funding for Lupus Detection and Management Platforms
    NextPrevious

    Progentec Gains Additional Funding for Lupus Detection and Management Platforms

    By sarah | News | 0 comment | 8 December, 2018 | 0

    By Mary Chapman
    Lupus News Today
    Copyright © 2013-2018 All rights reserved.

    Completion of a second round of funding could help bring closer to market Progentec Diagnostics‘ new tool for predicting lupus flares and a biomarker-based index that monitors underlying disease activity.

    Funding for Progentec’s biomarker-based diagnostic testing was led by venture capital outfits i2E and OCA Ventures, with participation by global healthcare provider NMC Lifesciences. Using technology created by the Oklahoma Medical Research Foundation, the platform is touted as being able to detect impending flares and track underlying disease movement.

    “Today’s funding round is the next step on our journey to making this and other advanced tools commercially available to patients with lupus, a disease that afflicts more than one million Americans, many of whom are women,” Mohan Purushothaman, PhD, Progentec’s CEO, said in a press release. “The Progentec tests will become powerful tools to help patients and healthcare providers stay ahead of lupus.”

    Read the entire story at Lupus News Today

     

     

    Lupus News Today, Mohan Purushothaman, Progentec Diagnostics

    Related Post

    • Linear Health Sciences Announces U.S. FDA Clearance and Health Canada Approval of its Orchid Safety Release Valve (SRV)

      By sarah | Comments are Closed

      Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals; Sister Product Orchid SRV-Type D for Drainage to Launch Simultaneously OKLAHOMA CITY, Okla. – May 17, 2022 – Medical device company LinearRead more

    • Student teams from OSU, TU and East Central claim Love’s Cup top awards

      By sarah | Comments are Closed

      May 3, 2022 Contact: Sarah Seagraves, Senior VP for Marketing (405) 813-2403 or email sseagraves@i2E.org Teams led by student innovators from Oklahoma State University, the University of Tulsa and East Central University claimed first placeRead more

    • A final column and a thank you for reading

      By sarah | Comments are Closed

      Thank you for reading this column for nearly a decade By Scott Meacham This is my final column for The Oklahoman. As CEO of i2E, I have had the wonderful opportunity since January 2013 to write thisRead more

    • A significant impact on new ventures? That’s i2E’s e3 program

      By sarah | Comments are Closed

      Accelerators like i2E’s e3 can have a significant impact on new ventures By Scott Meacham When the team from Zen Health Technologies formally introduces their company, they describe a business that uses immersive technologies for personalRead more

    • Autigen Announces Collaboration with Boehringer Ingelheim

      By sarah | 0 comment

      Novel Treatments for Hearing Loss Collaboration and licensing agreement to advance novel therapies for sensorineural hearing loss (SNHL), where there are currently no approved pharmacological therapies. OKLAHOMA CITY–(BUSINESS WIRE)– Autigen, a biotechnology portfolio company of theRead more

    Leave a Comment

    You must be logged in to post a comment.

    NextPrevious
    i2E-300dpi-Trans-Light
    • Events
    • News
    • Resources
    • Media
    • Love’s Cup

    Oklahoma City Office

    840 Research Parkway, Suite 250
    OKC, OK 73104
    PHONE 405/235-2305
    Click HERE for printable map with directions.

    Tulsa Office

    100 S. Cincinnati Ave – 5th Floor, Suite 514
    Tulsa, OK 74103
    PHONE 918/582-5592
    Copyright 2022 i2E, Inc. | All Rights Reserved
    • About
    • Entrepreneurship
      • Venture Advisory Services
      • Love’s Entrepreneur’s Cup
      • ACT Tulsa
    • e3
    • Concept Fund
    • Portfolio
    • iMCI
    • ACT Tulsa
    • Contact
    i2E